Literature DB >> 22308277

Polycomb segment myeloid malignancies.

Yogen Saunthararajah1, Jaroslaw Maciejewski.   

Abstract

An unexpected revelation of cancer genome studies has been frequent abnormality in genes for factors that modify chromatin, underscored in this issue of Blood by reports from Score et al and Kroeze et al of inactivating mutations and chromosome loss in SUZ12, EED and JARID2 in myelodysplastic syndrome (MDS) and myeloproliferative disease (MPD).

Entities:  

Year:  2012        PMID： 22308277     DOI： 10.1182/blood-2011-12-391268

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  8 in total

1.  Targets of opportunity for precision medicine.

Authors:  Yogen Saunthararajah
Journal:  Blood       Date:  2015-05-14       Impact factor: 22.113

2.  Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Authors:  Yogen Saunthararajah; Mikkael Sekeres; Anjali Advani; Reda Mahfouz; Lisa Durkin; Tomas Radivoyevitch; Ricki Englehaupt; Joy Juersivich; Kathleen Cooper; Holleh Husseinzadeh; Bartlomiej Przychodzen; Matthew Rump; Sean Hobson; Marc Earl; Ronald Sobecks; Robert Dean; Frederic Reu; Ramon Tiu; Betty Hamilton; Edward Copelan; Alan Lichtin; Eric Hsi; Matt Kalaycio; Jaroslaw Maciejewski
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

3.  Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer.

Authors:  Laxmi G Pellakuru; Tsuyoshi Iwata; Bora Gurel; Denise Schultz; Jessica Hicks; Carlise Bethel; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2012-06-17       Impact factor: 4.307

Review 4.  Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.

Authors:  V Visconte; H Makishima; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2012-05-15       Impact factor: 11.528

5.  Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Authors:  Xiaorong Gu; Zhenbo Hu; Quteba Ebrahem; John S Crabb; Reda Z Mahfouz; Tomas Radivoyevitch; John W Crabb; Yogen Saunthararajah
Journal:  J Biol Chem       Date:  2014-04-02       Impact factor: 5.157

6.  Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development.

Authors:  David Landeira; Hakan Bagci; Andrzej R Malinowski; Karen E Brown; Jorge Soza-Ried; Amelie Feytout; Zoe Webster; Elodie Ndjetehe; Irene Cantone; Helena G Asenjo; Neil Brockdorff; Thomas Carroll; Matthias Merkenschlager; Amanda G Fisher
Journal:  Cell Rep       Date:  2015-07-16       Impact factor: 9.423

Review 7.  MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Authors:  Julian Grabek; Jasmin Straube; Megan Bywater; Steven W Lane
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

8.  Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation.

Authors:  K P Ng; Z Hu; Q Ebrahem; S Negrotto; J Lausen; Y Saunthararajah
Journal:  Oncogenesis       Date:  2013-11-04       Impact factor: 7.485
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.